Data as of 3:59pm ET
| +0.06 / +0.33%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 35.00, with a high estimate of 44.50 and a low estimate of 24.00. The median estimate represents a +92.84% increase from the last price of 18.15.
The current consensus among 2 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.